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Introduction

Methods and Experimental Design

• Chimeric Antigen Receptor (CAR)-T cell therapy has made
remarkable strides in the treatment of patients with B-cell
malignancies and certain hematological cancers.
• Although CAR-T cells confer tumor antigen specificity,
success with solid tumors has been limited, partly due to
the metabolically hostile tumor microenvironment (TME).1
• Mitogen Activated Protein (MAP) kinase kinase kinase
(MAP3K) is a crucial triple kinase that mediates CAR-T cell
efficacy and is also a promising target for improving the
effectiveness of CAR-T cell therapy in solid tumors.2
• MAP3K is a highly labile protein because its degradation is
ubiquitin-dependent. This, however, can be prevented by
the deletion of its N-terminal portion.3 Due to MAP3K’s
essential role in CAR-T cell therapy, there is a clear
rationale for further investigating its mechanistic role as
well as developing methods to increase its stability.
• This study aims to construct a CAR-T cell that expresses a
stable form of MAP3K lacking its N-terminal region
(MAP3KΔN) with the hope of further improving the
antitumor efficacy of CAR-T cell therapy in solid tumors.
We hypothesize that MAP3KΔN expression will promote
CAR-T cell activation and metabolic fitness in the TME of
solid tumors.

1. Construct anti-human CD19 CAR expressing MAP3K∆N through
molecular cloning

Results

Figure 4. Restriction enzyme digestion confirmed successful synthesis of hCD19-MAP3KΔN-CAR
(method 1). The patterns obtained for clones 1, 2, 4, 5, 12, 17, 20 and 22 showed the expected band sizes
of approximately 3000 bp for MAP3KΔN and 8000 bp for hCD19-CAR.

Figure 5. Immunobloting analysis of HA protein tag expression in hCD19-MAP3KΔN-CAR plasmid
(method 1). The plasmid containing the MAP3K∆N sequence has an additional HA tag and its detection
allow us to confirm MAP3K∆N expression via immunoblotting. The presence of the protein HA associated
with MAP3KΔN was identified in clones 1, 2, 4, 20, and 22. Additionally, Sanger sequencing confirmed the
expected sequence for the plasmid (data not shown).

2. Test expression by transient expression (transfection) in HEK293T
cells and by infection (transduction) in OT1 CD8+ T cells

Figure 1. CAR-T cells face metabolic challenge in solid tumor
microenvironment. CAR-T cells become metabolically exhausted in the
hostile solid tumor microenvironment (TME) that includes the presence of
immunosuppressive molecules (TGFβ, IL-10, etc.) and cells (T-regs, MDSCs,
etc.) and lead to CAR T-cell hypofunctionality.4
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Figure 6. GFP expression in transduced OT1 mouse CD8+ T cells (method 2). CD8+ T cells from OT1
mice were isolated, activated, and transduced with the control CAR, MARP3KWT-CAR and MAP3KΔN-CAR.
The plasmids include a GFP construct and its expression allows to determine transduction efficacy. The
three groups expressed GFP confirming adequate transduction.

3. Generate mouse CAR-T cells by infecting CD8+ T cells with antihCD19 CAR-MAP3K∆N and examine tumor rejection using
B16F10-hCD19 melanoma mouse models
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Figure 2. MAP3K expression enhances CAR-T cell antitumor response,
which dramatically improves cancer prognosis. This MAP3K regulates T
cell metabolism via an NF-kB-independent mechanism that involves
stabilization of hexokinase 2 (HK2), which is a rate-limiting enzyme of the
glycolytic pathway and is required for metabolic reprogramming of activated T
cells. However, MAP3K is subject to ubiquitin-dependent degradation.
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Figure 7. Expression of MAP3KWT significantly slows down tumor progression and extends survival in vivo
(method 3). C57BL/6 mice were subcutaneously injected with B16-hCD19 expressed cells (2×105 cells / mouse) on the
ventral inguinal area and treated with MAP3KWT, MAP3KΔN, and control CAR for the indicated time periods. a. Tumor
growth curves highlight significant amelioration of tumor burden in B16 melanoma-bearing mice treated with MAP3KWT
compared to mice treated with MAP3KΔN . b. A survival graph underscores the success of MAP3KWT to extend the
lifespan of melanoma-bearing mice. c. Flow cytometric analysis after 3 days of in vitro culture of CAR-T cells using antiCD90.1 monoclonal antibody (Thy-1.1), APC, to detect transduction efficiency. CD90.1 is a surface marker on the CAR-T
cells that allows to distinguish them from B6 mice endogenous CD8+ T cells, which are CD90.2 positive. In this graph,
MAP3KΔN shows the highest transduction efficacy with a 58.7% rate. d. Flow cytometric analysis after three days of in
vitro culture of CAR-T cells using Blue Dead, PB, to identify dead cells in the samples. In this graph, MAP3KΔN displays a
28.1% of dead cells, which is much higher compared to the control CAR (6.36%) and MAP3KWT (9.40%). Surprisingly,
these data aptly support MAP3KWT as being a crucial promoter of CAR-T cell therapy compared to MAP3KΔN.
Summary data are mean±standard error of mean with P values being determined by two-way ANOVA with Bonferroni’s
post-test (a, b). *< 0.05, **<0.01, ***<0.001, ****<0.0001. Numbers in quadrants indicate percentage of cells (c, d).

Figure 3. Stabilization of MAP3K by deletion of its N-terminal end. Under
normal conditions, tumor necrosis factor receptor-associated factor 3
(TRAF3) physically associates with MAP3K via the N-terminal region, which
mediates ubiquitination and proteasomal degradation. This can be prevented
by deletion of its N-terminal portion.

Discussion and Conclusion

Future directions
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• We have found evidence to reject our hypothesis that MAP3KΔN will promote CAR-T cell efficacy
due to avoidance of degradation. However, MAP3KWT leads to a notable decrease in tumor growth in
vivo consistent with our previous observations. Several points remain to be addressed to define
cause-effect relationships and we propose further directions to enhance this promising
immunotherapy.
• We have concluded that expression of MAP3KWT, but not MAP3K∆N, profoundly improves the
antitumor function of CAR T cells.
• Our results suggest two hypotheses:
1. Optimal rather than excessive T cell activation is critical for potential therapeutic applications using
MAP3K expression.
2. Deletion of the N-terminal portion of MAP3K impairs its role in facilitating T cell metabolic functions.

•

Perform flow cytometric analysis of the tumor
microenvironment after injection of MAP3KΔN-CAR-T,
MAP3KWT-CAR-T and control CAR-T.

•
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Analyze for potential cytokine storm or organ inflammation.

•

Develop an inducible MAP3KWT expression system to
manipulate the metabolic activity and function of CAR-T
cells based on temporary MAP3KWT expression.

•

Apply MAP3KWT expression to tumor models beyond
melanoma to test its universality.
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